资源类型:
期刊
WOS体系:
Article
Pubmed体系:
Journal Article
收录情况:
◇ SCIE
文章类型:
论著
机构:
[1]Department of General Surgery, Wuhan Third Hospital (Tongren Hospital of Wuhan University).
[2]Department of Oncology, Wuhan Asia General Hospital, Wuhan, China.
ISSN:
0959-4973
关键词:
cholangiocarcinoma
miRNA-95-3p
SMARCA5
TRAF3
摘要:
Enhancing research indicatedthat circular RNA (circRNA) acted a critical part in cholangiocarcinoma (CHOL) development. This research aims to discover the role of circRNA SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 5 (SMARCA5) in CHOL bio-progression, which has been proved to be downregulated in CHOL tissues. In this study, quantitative reverse transcription polymerase chain reaction was used to reveal the level and linkage of circRNA SMARCA5, miRNA-95-3p and TNF receptor-associated factor 3 gene (TRAF3) in CHOL tissues and cancer cells. The target sites of circRNA SMARCA5 and miRNA-95-3p were forecast by Starbase, and Targetscan was conducted to forecast the potential linkage points of TRAF3 and miRNA-95-3p, and which is affirmed by double luciferase reporter assay. CCK-8 and flow cytometry assay was carried to indicate cell viability. And apoptosis-related protein was counted by caspase3 activity and Western blot assay. CircRNA SMARCA5 was downregulated in CHOL cell lines and cancer samples. Besides, over-expression of SMARCA5 inhibited cell growth and promoted apoptotic rate. Dual-luciferase reporter assays presented that miRNA-95-3p could link with circRNA SMARCA5. Moreover, miRNA-95-3p was discovered highly expressed in CHOL. Interference of miRNA-95-3p repressed cell proliferation and raised the apoptosis. Importantly, TRAF3 was validated to be a downstream of miRNA-95-3p. Strengthen of miRNA-95-3p reversed the inhibitory impact of circRNA SMARCA5-plasmid transfection, and the results of miRNA-95-3p inhibitor were reversed by si-TRAF3. CircRNA SMARCA5 is involved in CHOL development by interosculating miRNA-95-3p/TRAF3 axis and may become a novel approach for treating CHOL.Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
被引次数:
4
WOS:
WOS:001081838400005
PubmedID:
36727735
中科院(CAS)分区:
出版当年[2022]版:
大类
|
4 区
医学
小类
|
4 区
药学
4 区
肿瘤学
最新[2023]版:
大类
|
4 区
医学
小类
|
4 区
肿瘤学
4 区
药学
JCR分区:
出版当年[2021]版:
Q4
ONCOLOGY
Q4
PHARMACOLOGY & PHARMACY
最新[2023]版:
Q3
ONCOLOGY
Q3
PHARMACOLOGY & PHARMACY
影响因子:
1.8
最新[2023版]
1.9
最新五年平均
2.389
出版当年[2021版]
2.384
出版当年五年平均
2.248
出版前一年[2020版]
2.3
出版后一年[2022版]
第一作者:
Wang Guangxin
第一作者机构:
[1]Department of General Surgery, Wuhan Third Hospital (Tongren Hospital of Wuhan University).
共同第一作者:
Gao Xia
通讯作者:
Long Haocheng
通讯机构:
[1]Department of General Surgery, Wuhan Third Hospital (Tongren Hospital of Wuhan University).
[*1]Department of General Surgery, Wuhan Third Hospital (Tongren Hospital of Wuhan University), No. 241, Pengliuyang Road, Wuchang District, Wuhan 430060, China
推荐引用方式(GB/T 7714):
Wang Guangxin,Gao Xia,Sun Zhijun,et al.Circular RNA SMARCA5 inhibits cholangiocarcinoma via microRNA-95-3p/tumor necrosis factor receptor associated factor 3 axis[J].ANTI-CANCER DRUGS.2023,34(9):1002-1009.doi:10.1097/CAD.0000000000001487.
APA:
Wang Guangxin,Gao Xia,Sun Zhijun,He Tianyou,Huang Chaogang...&Long Haocheng.(2023).Circular RNA SMARCA5 inhibits cholangiocarcinoma via microRNA-95-3p/tumor necrosis factor receptor associated factor 3 axis.ANTI-CANCER DRUGS,34,(9)
MLA:
Wang Guangxin,et al."Circular RNA SMARCA5 inhibits cholangiocarcinoma via microRNA-95-3p/tumor necrosis factor receptor associated factor 3 axis".ANTI-CANCER DRUGS 34..9(2023):1002-1009